Welcome!

News Feed Item

Mania Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Mania Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256138/Mania-Global-Clinical-Trials-Review-H2-2014.html

Mania Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Mania Global Clinical Trials Review, H2, 2014" provides data on the Mania clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mania. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mania. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6

Mania 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Mania to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Mania to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Mania 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Mania Therapeutics Clinical Trials 30
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
AstraZeneca PLC 32

Clinical Trial Overview of AstraZeneca PLC 32
Pfizer Inc. 34
Clinical Trial Overview of Pfizer Inc. 34
Abbott Laboratories 35
Clinical Trial Overview of Abbott Laboratories 35
Johnson & Johnson 36
Clinical Trial Overview of Johnson & Johnson 36
Otsuka Holdings Co., Ltd. 37
Clinical Trial Overview of Otsuka Holdings Co., Ltd. 37
Eli Lilly and Company 38
Clinical Trial Overview of Eli Lilly and Company 38
Richter Gedeon Nyrt. 39

Clinical Trial Overview of Richter Gedeon Nyrt. 39
Actavis plc 40
Clinical Trial Overview of Actavis plc 40
Bristol-Myers Squibb Company 41
Clinical Trial Overview of Bristol-Myers Squibb Company 41
Bluefish Pharmaceuticals AB 42
Clinical Trial Overview of Bluefish Pharmaceuticals AB 42
Clinical Trial Overview of Top Institutes / Government 43
Massachusetts General Hospital 43
Clinical Trial Overview of Massachusetts General Hospital 43
University of Cincinnati 44
Clinical Trial Overview of University of Cincinnati 44
Mclean Hospital 45
Clinical Trial Overview of Mclean Hospital 45
University of Leipzig 46

Clinical Trial Overview of University of Leipzig 46
Cedars-Sinai Medical Center 47
Clinical Trial Overview of Cedars-Sinai Medical Center 47
University of British Columbia 48
Clinical Trial Overview of University of British Columbia 48
Eunice Kennedy Shriver National Institute of Child Health and Human Development 49
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 49
National Institute of Mental Health 50
Clinical Trial Overview of National Institute of Mental Health 50
University of Texas Southwestern Medical Center at Dallas 51
Clinical Trial Overview of University of Texas Southwestern Medical Center at Dallas 51
Mashhad University of Medical Sciences 52
Clinical Trial Overview of Mashhad University of Medical Sciences 52
Five Key Clinical Profiles 53
Appendix 114
Abbreviations 114
Definitions 114
Research Methodology 115
Secondary Research 115
About GlobalData 116
Contact Us 116
Disclaimer 116
Source 116

List of Tables

Mania Therapeutics, Global, Clinical Trials by Region, 2014* 7
Mania Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Mania Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Mania Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Mania Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Mania Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Mania Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Mania Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Mania to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Mania Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Mania Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Mania to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Mania Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Mania Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Mania Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Mania Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22

Mania Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Mania Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Mania Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Mania Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Mania Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Mania Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Mania Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Mania Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Mania Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 32
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 34
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories, 2014* 35
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014* 36
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Otsuka Holdings Co., Ltd., 2014* 37

Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 38
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Richter Gedeon Nyrt., 2014* 39
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Actavis plc, 2014* 40
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 41
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Bluefish Pharmaceuticals AB, 2014* 42
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 43
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Cincinnati, 2014* 44
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Mclean Hospital, 2014* 45
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Leipzig, 2014* 46
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Cedars-Sinai Medical Center, 2014* 47
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of British Columbia, 2014* 48

Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 49
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Mental Health, 2014* 50
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Texas Southwestern Medical Center at Dallas, 2014* 51
Mania Therapeutics Clinical Trials Market, Global, Clinical Trials by Mashhad University of Medical Sciences, 2014* 52

List of Figures

Mania Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Mania Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Mania Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Mania Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Mania Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Mania Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Mania Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Mania Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Mania to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Mania Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Mania Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Mania to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Mania Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Mania Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20

Mania Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Mania Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Mania Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Mania Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Mania Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Mania Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Mania Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Mania Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Mania Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 115

To order this report: Mania Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256138/Mania-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
Whether they’re located in a public, private, or hybrid cloud environment, cloud technologies are constantly evolving. While the innovation is exciting, the end mission of delivering business value and rapidly producing incremental product features is paramount. In his session at @DevOpsSummit at 19th Cloud Expo, Kiran Chitturi, CTO Architect at Sungard AS, discussed DevOps culture, its evolution of frameworks and technologies, and how it is achieving maturity. He also covered various styles and...
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.
Some people worry that OpenStack is more flash then substance; however, for many customers this could not be farther from the truth. No other technology equalizes the playing field between vendors while giving your internal teams better access than ever to infrastructure when they need it. In his session at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will talk through some real-world OpenStack deployments and look into the ways this can benefit customers of all sizes....
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin, ...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his general session at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore...
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Both SaaS vendors and SaaS buyers are going “all-in” to hyperscale IaaS platforms such as AWS, which is disrupting the SaaS value proposition. Why should the enterprise SaaS consumer pay for the SaaS service if their data is resident in adjacent AWS S3 buckets? If both SaaS sellers and buyers are using the same cloud tools, automation and pay-per-transaction model offered by IaaS platforms, then why not host the “shrink-wrapped” software in the customers’ cloud? Further, serverless computing, cl...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
SYS-CON Events announced today that DatacenterDynamics has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY. DatacenterDynamics is a brand of DCD Group, a global B2B media and publishing company that develops products to help senior professionals in the world's most ICT dependent organizations make risk-based infrastructure and capacity decisions.
"Matrix is an ambitious open standard and implementation that's set up to break down the fragmentation problems that exist in IP messaging and VoIP communication," explained John Woolf, Technical Evangelist at Matrix, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Growth hacking is common for startups to make unheard-of progress in building their business. Career Hacks can help Geek Girls and those who support them (yes, that's you too, Dad!) to excel in this typically male-dominated world. Get ready to learn the facts: Is there a bias against women in the tech / developer communities? Why are women 50% of the workforce, but hold only 24% of the STEM or IT positions? Some beginnings of what to do about it! In her Day 2 Keynote at 17th Cloud Expo, Sandy Ca...
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and micro services. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your contain...